2025 Q4 -tulosraportti
50 päivää sitten
‧13 min
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 12.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
29.3.29.3.CEO nyt fra LinkedIn: Great to spend time at #ACC with Ken Nelson, whose experience and perspective continue to be incredibly valuable as we scale Acarix in the U.S. and beyond. What stands out most is the convergence we are seeing across the ecosystem. Conversations with customers, partners, and industry leaders are no longer siloed. Commercial strategy, R&D innovation, and collaborative partnerships are aligning in a very real way. From a commercial standpoint, there is growing clarity around how #CADScor can be integrated into clinical workflows to drive better patient outcomes while reducing unnecessary testing. That alignment is critical as we continue to expand access and adoption. On the innovation side, our ongoing work in both CAD and heart failure is opening the door to a broader platform approach at the point of care. The ability to provide fast, actionable insights in minutes is resonating more than ever with clinicians and health systems. Equally important are the strategic discussions happening around collaboration.·29.3.Last part: Whether with providers, payors, or potential partners, there is a shared recognition that solving large scale healthcare challenges requires alignment, not fragmentation. We are building meaningful momentum, and it is being driven by the right conversations with the right people at the right time. Excited for what is ahead. #Acarix #HealthcareInnovation #Cardiology #PointOfCare #MedTech #Leadership
·25.3.The endless lost cause. ;) Just sit back and only look at the price in 3 years. Either it's worth much more, or it says 0kr.
·23.3.A lot on the buy side now. I don't understand why more aren't buying. It's very cheap now, after all. Perhaps people are waiting for good news, but by then it will have already gone up.
·28.3.I think you are confusing heart rhythm diagnosis with wearables, and diagnosis of calcification in the coronary arteries (CAD). An Apple Watch can see if your heart beats rhythmically, but it cannot 'hear' the turbulent sounds from a narrowing. The acoustic AI, which Acarix has spent 10 years and 60,000 patients perfecting, can. The reason for the 'desert wandering' has not been the technology, but a lack of funding for the hospitals. This is exactly what is changing NOW with the RHT funds in the USA. E.g., 281 million USD in Texas alone, everyone gets money. To say that GE can just make it in a week ignores the 5-10 years of clinical studies and regulatory approvals (FDA/MDR), which are the real barrier. You can't just 'print' a medical approval, no matter how big you are. To me, it seems your glass is always half empty..yes, it has and takes a long time, but look at the results just from the last 2 years. I actually think that Amir and Co. are doing a fantastic job.- 13.3.13.3.MIB174 Listing: The CADScor system was included in a NICE (National Institute for Health and Care Excellence) Medtech Innovation Briefing (MIB174) in March 2019. Den 10.Marts 2026 var CADScor'en belyst i en artikel fra Oxford Acedemic, Louise . Bjerking mf.: "Journal Article Optimizing diagnostic resource use in suspected chronic coronary syndrome: pre-test probability and acoustic CAD rule-out in the FILTER-SCAD trial". Aims The FILTER-SCAD trial combined pre-test-probability (PTP) and the FDA-cleared coronary artery disease (CAD)-Score System to guide and improve deferred testing in suspected chronic coronary syndrome (CCS). However, adherence to the recommended strategy was low, with fewer than one-fourth of patients deferred. This study evaluates the potential of a PTP- and CAD-score-based deferral strategy on diagnostic resource consumption and clinical outcomes. Methods and results This observational post-hoc analysis included 1002 patients from the FILTER-SCAD intervention arm. Deferred testing was recommended for PTP ≤5% and/or CAD-score ≤20. We calculated the number of potentially deferred tests and clinical outcomes, including significant CAD and major adverse cardiac events (MACE). A deferred testing strategy could nearly double the number of safely deferred tests, reducing overall diagnostic test (n = 1043) volume by 275 tests (26%). Deferral based on PTP ≤5% alone would avoid unnecessary testing in 13.5% of patients, with an additional 31.3% deferrable based on CAD-score ≤20 (using the 2024 European Society of Cardiology risk factor-weighted likelihood increased deferral from 38.8% to 51.4%). Among the 135 low-likelihood patients (PTP ≤5%), 43.7% underwent testing, with only one (0.7%) positive test result, no invasive coronary angiographies, and no MACE. Among patients with CAD-score ≤20 tested (n = 209), 2.1% had positive test results, 1.9% were revascularized and there were two MACE. Conversely, 11.4% of the 596 higher likelihood patients (PTP >5%) were revascularized, and 20 patients experienced a MACE. Conclusion A strategy incorporating PTP and CAD-score can safely reduce unnecessary testing in low-likelihood CCS patients, optimizing resource use without compromising outcomes. Kilde: https://academic.oup.com/ehjdh/article/7/2/ztaf151/8416611
- ·12.3. · MuokattuUSA: The RHTP initiative is seen as an opportunity to reduce unnecessary, expensive and invasive diagnostic procedures in rural areas, which is like a penalty kick against a drunk Russian. We are very close to a resolution, and since CMS already includes CADScor in their fixed reimbursement I see it as yet another plus. MENA: the war has probably scared some, but planes still deliver air freight to UAE etc. which is why this does not prevent the estimated 6.8 mill. SEK from being reached at the beginning of Q3. CEO has in the last 2-9 months confirmed that Kapacitet has multiplied the production of units and plastics several times over. Trend: We are with 0.2760 SEK up by 3% for the year. Number of owners in Nordnet: 1372, and thus only 4 persons from ath. Whether this indicates that a consolidation has occurred can be discussed, but everyone seems to hold and await the market value of the holding getting the deserved boost.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
50 päivää sitten
‧13 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 29.3.29.3.CEO nyt fra LinkedIn: Great to spend time at #ACC with Ken Nelson, whose experience and perspective continue to be incredibly valuable as we scale Acarix in the U.S. and beyond. What stands out most is the convergence we are seeing across the ecosystem. Conversations with customers, partners, and industry leaders are no longer siloed. Commercial strategy, R&D innovation, and collaborative partnerships are aligning in a very real way. From a commercial standpoint, there is growing clarity around how #CADScor can be integrated into clinical workflows to drive better patient outcomes while reducing unnecessary testing. That alignment is critical as we continue to expand access and adoption. On the innovation side, our ongoing work in both CAD and heart failure is opening the door to a broader platform approach at the point of care. The ability to provide fast, actionable insights in minutes is resonating more than ever with clinicians and health systems. Equally important are the strategic discussions happening around collaboration.·29.3.Last part: Whether with providers, payors, or potential partners, there is a shared recognition that solving large scale healthcare challenges requires alignment, not fragmentation. We are building meaningful momentum, and it is being driven by the right conversations with the right people at the right time. Excited for what is ahead. #Acarix #HealthcareInnovation #Cardiology #PointOfCare #MedTech #Leadership
- ·25.3.The endless lost cause. ;) Just sit back and only look at the price in 3 years. Either it's worth much more, or it says 0kr.
- ·23.3.A lot on the buy side now. I don't understand why more aren't buying. It's very cheap now, after all. Perhaps people are waiting for good news, but by then it will have already gone up.·28.3.I think you are confusing heart rhythm diagnosis with wearables, and diagnosis of calcification in the coronary arteries (CAD). An Apple Watch can see if your heart beats rhythmically, but it cannot 'hear' the turbulent sounds from a narrowing. The acoustic AI, which Acarix has spent 10 years and 60,000 patients perfecting, can. The reason for the 'desert wandering' has not been the technology, but a lack of funding for the hospitals. This is exactly what is changing NOW with the RHT funds in the USA. E.g., 281 million USD in Texas alone, everyone gets money. To say that GE can just make it in a week ignores the 5-10 years of clinical studies and regulatory approvals (FDA/MDR), which are the real barrier. You can't just 'print' a medical approval, no matter how big you are. To me, it seems your glass is always half empty..yes, it has and takes a long time, but look at the results just from the last 2 years. I actually think that Amir and Co. are doing a fantastic job.
- 13.3.13.3.MIB174 Listing: The CADScor system was included in a NICE (National Institute for Health and Care Excellence) Medtech Innovation Briefing (MIB174) in March 2019. Den 10.Marts 2026 var CADScor'en belyst i en artikel fra Oxford Acedemic, Louise . Bjerking mf.: "Journal Article Optimizing diagnostic resource use in suspected chronic coronary syndrome: pre-test probability and acoustic CAD rule-out in the FILTER-SCAD trial". Aims The FILTER-SCAD trial combined pre-test-probability (PTP) and the FDA-cleared coronary artery disease (CAD)-Score System to guide and improve deferred testing in suspected chronic coronary syndrome (CCS). However, adherence to the recommended strategy was low, with fewer than one-fourth of patients deferred. This study evaluates the potential of a PTP- and CAD-score-based deferral strategy on diagnostic resource consumption and clinical outcomes. Methods and results This observational post-hoc analysis included 1002 patients from the FILTER-SCAD intervention arm. Deferred testing was recommended for PTP ≤5% and/or CAD-score ≤20. We calculated the number of potentially deferred tests and clinical outcomes, including significant CAD and major adverse cardiac events (MACE). A deferred testing strategy could nearly double the number of safely deferred tests, reducing overall diagnostic test (n = 1043) volume by 275 tests (26%). Deferral based on PTP ≤5% alone would avoid unnecessary testing in 13.5% of patients, with an additional 31.3% deferrable based on CAD-score ≤20 (using the 2024 European Society of Cardiology risk factor-weighted likelihood increased deferral from 38.8% to 51.4%). Among the 135 low-likelihood patients (PTP ≤5%), 43.7% underwent testing, with only one (0.7%) positive test result, no invasive coronary angiographies, and no MACE. Among patients with CAD-score ≤20 tested (n = 209), 2.1% had positive test results, 1.9% were revascularized and there were two MACE. Conversely, 11.4% of the 596 higher likelihood patients (PTP >5%) were revascularized, and 20 patients experienced a MACE. Conclusion A strategy incorporating PTP and CAD-score can safely reduce unnecessary testing in low-likelihood CCS patients, optimizing resource use without compromising outcomes. Kilde: https://academic.oup.com/ehjdh/article/7/2/ztaf151/8416611
- ·12.3. · MuokattuUSA: The RHTP initiative is seen as an opportunity to reduce unnecessary, expensive and invasive diagnostic procedures in rural areas, which is like a penalty kick against a drunk Russian. We are very close to a resolution, and since CMS already includes CADScor in their fixed reimbursement I see it as yet another plus. MENA: the war has probably scared some, but planes still deliver air freight to UAE etc. which is why this does not prevent the estimated 6.8 mill. SEK from being reached at the beginning of Q3. CEO has in the last 2-9 months confirmed that Kapacitet has multiplied the production of units and plastics several times over. Trend: We are with 0.2760 SEK up by 3% for the year. Number of owners in Nordnet: 1372, and thus only 4 persons from ath. Whether this indicates that a consolidation has occurred can be discussed, but everyone seems to hold and await the market value of the holding getting the deserved boost.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 12.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
50 päivää sitten
‧13 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 12.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 29.3.29.3.CEO nyt fra LinkedIn: Great to spend time at #ACC with Ken Nelson, whose experience and perspective continue to be incredibly valuable as we scale Acarix in the U.S. and beyond. What stands out most is the convergence we are seeing across the ecosystem. Conversations with customers, partners, and industry leaders are no longer siloed. Commercial strategy, R&D innovation, and collaborative partnerships are aligning in a very real way. From a commercial standpoint, there is growing clarity around how #CADScor can be integrated into clinical workflows to drive better patient outcomes while reducing unnecessary testing. That alignment is critical as we continue to expand access and adoption. On the innovation side, our ongoing work in both CAD and heart failure is opening the door to a broader platform approach at the point of care. The ability to provide fast, actionable insights in minutes is resonating more than ever with clinicians and health systems. Equally important are the strategic discussions happening around collaboration.·29.3.Last part: Whether with providers, payors, or potential partners, there is a shared recognition that solving large scale healthcare challenges requires alignment, not fragmentation. We are building meaningful momentum, and it is being driven by the right conversations with the right people at the right time. Excited for what is ahead. #Acarix #HealthcareInnovation #Cardiology #PointOfCare #MedTech #Leadership
- ·25.3.The endless lost cause. ;) Just sit back and only look at the price in 3 years. Either it's worth much more, or it says 0kr.
- ·23.3.A lot on the buy side now. I don't understand why more aren't buying. It's very cheap now, after all. Perhaps people are waiting for good news, but by then it will have already gone up.·28.3.I think you are confusing heart rhythm diagnosis with wearables, and diagnosis of calcification in the coronary arteries (CAD). An Apple Watch can see if your heart beats rhythmically, but it cannot 'hear' the turbulent sounds from a narrowing. The acoustic AI, which Acarix has spent 10 years and 60,000 patients perfecting, can. The reason for the 'desert wandering' has not been the technology, but a lack of funding for the hospitals. This is exactly what is changing NOW with the RHT funds in the USA. E.g., 281 million USD in Texas alone, everyone gets money. To say that GE can just make it in a week ignores the 5-10 years of clinical studies and regulatory approvals (FDA/MDR), which are the real barrier. You can't just 'print' a medical approval, no matter how big you are. To me, it seems your glass is always half empty..yes, it has and takes a long time, but look at the results just from the last 2 years. I actually think that Amir and Co. are doing a fantastic job.
- 13.3.13.3.MIB174 Listing: The CADScor system was included in a NICE (National Institute for Health and Care Excellence) Medtech Innovation Briefing (MIB174) in March 2019. Den 10.Marts 2026 var CADScor'en belyst i en artikel fra Oxford Acedemic, Louise . Bjerking mf.: "Journal Article Optimizing diagnostic resource use in suspected chronic coronary syndrome: pre-test probability and acoustic CAD rule-out in the FILTER-SCAD trial". Aims The FILTER-SCAD trial combined pre-test-probability (PTP) and the FDA-cleared coronary artery disease (CAD)-Score System to guide and improve deferred testing in suspected chronic coronary syndrome (CCS). However, adherence to the recommended strategy was low, with fewer than one-fourth of patients deferred. This study evaluates the potential of a PTP- and CAD-score-based deferral strategy on diagnostic resource consumption and clinical outcomes. Methods and results This observational post-hoc analysis included 1002 patients from the FILTER-SCAD intervention arm. Deferred testing was recommended for PTP ≤5% and/or CAD-score ≤20. We calculated the number of potentially deferred tests and clinical outcomes, including significant CAD and major adverse cardiac events (MACE). A deferred testing strategy could nearly double the number of safely deferred tests, reducing overall diagnostic test (n = 1043) volume by 275 tests (26%). Deferral based on PTP ≤5% alone would avoid unnecessary testing in 13.5% of patients, with an additional 31.3% deferrable based on CAD-score ≤20 (using the 2024 European Society of Cardiology risk factor-weighted likelihood increased deferral from 38.8% to 51.4%). Among the 135 low-likelihood patients (PTP ≤5%), 43.7% underwent testing, with only one (0.7%) positive test result, no invasive coronary angiographies, and no MACE. Among patients with CAD-score ≤20 tested (n = 209), 2.1% had positive test results, 1.9% were revascularized and there were two MACE. Conversely, 11.4% of the 596 higher likelihood patients (PTP >5%) were revascularized, and 20 patients experienced a MACE. Conclusion A strategy incorporating PTP and CAD-score can safely reduce unnecessary testing in low-likelihood CCS patients, optimizing resource use without compromising outcomes. Kilde: https://academic.oup.com/ehjdh/article/7/2/ztaf151/8416611
- ·12.3. · MuokattuUSA: The RHTP initiative is seen as an opportunity to reduce unnecessary, expensive and invasive diagnostic procedures in rural areas, which is like a penalty kick against a drunk Russian. We are very close to a resolution, and since CMS already includes CADScor in their fixed reimbursement I see it as yet another plus. MENA: the war has probably scared some, but planes still deliver air freight to UAE etc. which is why this does not prevent the estimated 6.8 mill. SEK from being reached at the beginning of Q3. CEO has in the last 2-9 months confirmed that Kapacitet has multiplied the production of units and plastics several times over. Trend: We are with 0.2760 SEK up by 3% for the year. Number of owners in Nordnet: 1372, and thus only 4 persons from ath. Whether this indicates that a consolidation has occurred can be discussed, but everyone seems to hold and await the market value of the holding getting the deserved boost.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt